Fish Leap Medical: Plans to conduct foreign exchange hedging business not exceeding 300 million US dollars.

Fishleap Medical announced that in order to prevent fluctuations in exchange rates and interest rates, the company and its holding subsidiaries plan to carry out foreign exchange hedging operations involving currencies such as the US dollar and Euro, including forward exchange transactions and foreign exchange swaps. The transaction amount at any point within the limit period shall not exceed 300 million US dollars or the equivalent in RMB, with a maximum margin limit of 20 million US dollars or the equivalent in RMB, a validity period of 12 months, and the source of funds being self-owned and other legal funds. This matter has been approved by the board of directors, does not require approval by the shareholders' meeting, and does not constitute a related party transaction. At the same time, the company has warned of market, liquidity, and other risks, and has formulated corresponding control measures.